In the last quarter of 2014, EpiFix, a dehydrated human amnion/chorion membrane (dHACM) allograft, underwent a randomized / controlled trial comparison against a leading living-cell based skin substitute, Apligraf. The EpiFix product was shown to heal twice as many skin wounds in half the time, and at one-fifth the cost, compared with Apligraf.
MiMedx, the creator of EpiFix, has also developed two additional products from human placental tissue. AmnioFix is expected have multiple applications in the fields of urology and gynecology, while CollaFix could yield superior results in ligament and tendon repairs. The company's proprietary Purion process was developed to retain all of the important qualities of "fresh human amniotic tissue" when fabricating their wound care products.
Bill Taylor President & COO: MiMedx